Clinical Trials Logo
  1. Home
  2. Cardiorenal Syndrome
  3. NCT03836482

Selective Cytopheretic Device (SCD) Trial

Cardiorenal Syndrome Clinical Trial

Official title:
Pilot Study to Assess the Safety and Efficacy of a Selective Cytopheretic Device to Treat ICU Patients With Acute or Chronic Systolic Heart Failure With Cardiorenal Syndrome(CRS) Awaiting Left Ventricular Assist Device (LVAD) Implantation

Clinical Trial Summary

The purpose of this study is to evaluate the selective cytopheretic device on the immune dysregulated state of congestive heart failure(CHF) with CRS and to assess the benefit of the device to improve cardiovascular and renal function. The study will enroll eligible patients in the ICU with acute on chronic systolic heart failure and worsening renal function due to cardiorenal syndrome while awaiting LVAD implantation. In this study patients who are eligible and agree to participate will receive treatment with the SCD. The treatment will be for 6 hours a day up to 6 days. Additionally, participants will have additional study procedures and be evaluated to determine if their kidney function improves enough to undergo LVAD implantation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03836482
Study type Interventional
Source University of Michigan
Contact
Status Suspended
Phase N/A
Start date November 11, 2019
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Suspended NCT04589065 - SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device) N/A
Not yet recruiting NCT02238093 - Cardiorenal Syndrome in End-Stage Kidney Disease N/A
Completed NCT01265615 - Paricalcitol Versus Calcitriol for the Management of Renocardiac Syndrome in Renal Transplant Patients Phase 4
Completed NCT03039959 - Predictive Value of Renal Venous Flow Profiles for Adverse Outcomes in Right Heart Failure
Recruiting NCT06111768 - Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study Phase 2
Withdrawn NCT02644057 - Dobutamaine Versus Milrinone in Cardiorenal Syndrome Phase 2
Completed NCT01570153 - Biomonitoring and Cardiorenal Syndrome in Heart Failure(BIONICS-HF) Trial N/A
Completed NCT05927285 - Effect on Kidney Function Recovery Guiding Decongestion With VExUS in Patients With Cardiorenal Syndrome 1 N/A
Completed NCT03183323 - Implementation of Telerehabilitation In Support of HOme-based Physical Exercise for Heart Failure N/A
Completed NCT04917497 - Levosimendan Infusion in Critically Ill Patients With Cardiogenic Shock
Completed NCT04227977 - Volume Optimization Incorporating Negative Pressure Diuresis in Heart Failure (VOID-HF) N/A
Recruiting NCT03684876 - Association Between Renal and Right Cardiac Functions After Urinary Sodium Depletion Following Cardiac Surgery
Completed NCT04393493 - The Effect in Renal Function on Patients With Type 1 Cardiorenal Syndrome Treated With Two Strategies of Furosemide. Phase 2
Completed NCT04145635 - The Aortix CRS Pilot Study N/A
Completed NCT02372292 - Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure N/A
Terminated NCT01364636 - Accuracy of Urinary NGAL in Predicting CardioRenal Syndrome in Acute Heart Failure at Emergency - CYNDERELA-HF Study
Completed NCT04116034 - Alfapump Direct Sodium Removal (DSR) Feasibility Study N/A
Terminated NCT00348556 - Use of Nesiritide (BNP) in Kidney Function in Patients With Congestive Heart Failure (CHF) and Kidney Failure Phase 1/Phase 2
Completed NCT03753607 - Renal Venous Flow and Cardiac Surgery-associated Acute Kidney Injury
Recruiting NCT05677100 - Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure N/A